Business
Dow is a global materials science company built around commodity and specialty chemicals, with integrated assets, feedstock exposure, and customers across infrastructure, mobility, consumer, and industrial markets.
Dow is in a deep chemical downcycle: sales fell, cash turned negative, and debt rose.
The read at a glance✓ Audited against SEC data
- Growth — Revenue -7.0% to $39.97BWatch
- Profitability — Net loss $2.44BWatch
- Cash quality — OCF -64.6%; FCF -$1.45BWatch
- Margins — Gross -438 bps; net -891 bpsWatch
- Capital — Buybacks stopped; dividends -24.2%Watch
- Accounting — Altman distress; no Beneish flagWatch
- Insiders — 0 buys / 0 sellsNote
Where the revenue comes from
Fiscal 2025, as DOW INC. reports it. History and quarterly detail are in the app.
- Packaging & Specialty Plastics$20.0B
- Industrial Intermediates & Infrastructure$11.2B
- Performance Materials & Coatings$8.1B
- Corporate$701.0M
Leadership changes
From DOW INC.'s own filings, the day they're filed.
- Jim Fitterling · Executive Chair · appointmenteff. 2026-07-01
- Karen S. Carter · Chief Executive Officer · appointmenteff. 2026-07-01
- Andre Argenton · Chief Sustainability Officer · appointmenteff. 2026-06-30
Latest filings
- 10-Q · Quarterly report2026-07-24
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-07-10
- 10-Q · Quarterly report2026-04-24
- 8-K · Company announcement2026-04-23
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about DOW INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.